Market Insider: EV Charging Realities, Pharma Breakouts, and Under-the-Radar Movers

There is more to this week's US market than just Big Tech. I'm told that a disjointed group of under-the-radar equities is currently undergoing the most significant overhaul we've seen since late 2025. As the Q1 2026 earnings season wraps up, the divergence between struggling EV infrastructure players and surging biotech names is becoming impossible to ignore.

Equifax (EFX.US)

The data analytics giant has delivered a surprisingly strong quarter. According to recent Q1 2026 filings, the company comfortably beat Wall Street EPS estimates. People familiar with the matter suggest that a more favorable macroeconomic backdrop has been the primary driver behind this outperformance, pushing Equifax to outpace the broader market recently.

Crinetics Pharmaceuticals (CRNX.US)

This is arguably the standout performer of the group. Driven by a narrower-than-expected loss in its Q1 2026 report, Crinetics saw another massive surge, bringing its year-to-date gains close to 100%. According to people familiar with the matter, optimism regarding the commercialization of its pipeline has reached a new high.

ChargePoint (CHPT.US) & Blink Charging (BLNK.US)

The EV charging sector is facing a brutal reality check. ChargePoint has seen its stock sink recently following weak forward guidance. Its rival, Blink Charging, is similarly bogged down, languishing near historic lows. I'm told that slowing industry demand and relentless margin pressures will remain the biggest headaches for both companies later this year.

Alarum Technologies (ALAR.US)

This tech firm experienced a sudden spike this week. Following an update regarding its proxy network business, Alarum shares leaped over 20% intraday. This marks one of the most aggressive single-day inflows for the company in recent months.

Nova Minerals (NVA.US) & Gain Therapeutics (GANX.US)

Among the smaller caps, Nova Minerals has faced notable pullback pressure, sliding more than 7% over the past week. Conversely, Gain Therapeutics managed a modest recovery, up nearly 4% in the same period, highlighting a stark contrast in risk appetite across micro-cap sectors.

Also

• Golden Minerals (AUMN.US): The stock remains sluggish as investors await further clarity on its mining operations.
• CBL International (BANL.US): The marine fuel logistics provider is seeing relatively flat trading action this month.
• Bristol-Myers Squibb CVR (CELG.RT.US): The contingent value right continues to fluctuate based on the long-term clinical progress of its parent company.

This article does not constitute investment advice.